The MM+M Podcast 9.9.2020: Alexion Pharmaceuticals’ Tamar Thompson
Tamar Thompson, VP of government affairs and policy at Alexion Pharmaceuticals, speaks about how the biotech company has evolved on the D&I front.
Tamar Thompson, VP of government affairs and policy at Alexion Pharmaceuticals, speaks about how the biotech company has evolved on the D&I front.
Marketers and consultants across biopharma, med-tech and agency recall the marketing milestones that defined the past year.
Ramaswami was most recently at rbb Communications and spent much of his career in pharma, including roles at J&J, Pfizer, and Merck.
John Jorden is executive director, Amgen Digital Health at Amgen.
Jay Appel is executive director of Bristol-Myers Squibb.
Is technology causing agencies to become more specialized? Is there still a need for the human connection?
Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech
Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer
Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds